Correction to: Nature Reviews Endocrinology https://doi.org/10.1038/s41574-023-00816-5. Published online 13 March 2023.
In the version of this article initially published, there was an error in the ‘Teplizumab (anti-CD3)’ box in Figure 3, where the description now reading “Binds to and inactivates CD3+CD8+ T cells” appeared originally as “Binds to and depletes CD3+ T cells.” The correction has been made in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tatovic, D., Narendran, P. & Dayan, C.M. Author Correction: A perspective on treating type 1 diabetes mellitus before insulin is needed. Nat Rev Endocrinol 19, 371 (2023). https://doi.org/10.1038/s41574-023-00837-0
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41574-023-00837-0
This article is cited by
-
ZHX2 inhibits diabetes-induced liver injury and ferroptosis by epigenetic silence of YTHDF2
Nutrition & Diabetes (2025)
-
CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes
Cardiovascular Diabetology (2025)
-
Lipid profile alterations and biomarker identification in type 1 diabetes mellitus patients under glycemic control
BMC Endocrine Disorders (2024)
